AbCellera acquires Trianni for $90M

By The Science Advisory Board staff writers

November 19, 2020 -- Artificial intelligence-powered biotech and drug discovery platform AbCellera has purchased Trianni for $90 million. The deal boosts AbCellera's ability to create large human antibody databases for drug discovery.

Trianni develops humanized mice used in drug trials, AbCellera said. Its mice help drug developers investigate multispecific antibodies and immune tolerance as well as target new epitopes.

Adding Trianni to its business expands AbCellera's platform, which currently includes microfluidic single-cell screening, repertoire sequencing, and bispecific protein engineering, according to the firm.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.